Launch of an interregional clinical trial for TNBC with the advanced cellular drug aHyC

The overall objective of the project is to launch an interregional clinical trial for the treatment of triple-negative breast cancer (TNBC) with the aHyC cell vaccine. The aim is to create the possibility of providing advanced personalised cancer therapies in an accessible and affordable context, developing innovation capabilities through the introduction of advanced technologies.

• Total amount: € 749,059.60
• VivaBioCell project amount: € 127,064.00
• VivaBioCell funding: € 0

Partners:

• Celica, biomedicinski center, d.o.o.
• Onkološki inštitut Ljubljana
• VivaBioCell S.p.A.
• Università degli studi di Udine
• Azienda Sanitaria Universitaria Friuli Centrale
• Zavod Republike Slovenije za transfuzijsko medicino